Related Experiment Videos
Pharmacogenetics: implications for therapy in rheumatic diseases.
Lesley Davila1, Prabha Ranganathan
1Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
Nature Reviews. Rheumatology
|August 10, 2011
Summary
Pharmacogenetics helps tailor treatments for rheumatic diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus. Understanding genetic variations can optimize drug responses for disease-modifying antirheumatic drugs (DMARDs) and biologics.
Area of Science:
- Rheumatology
- Pharmacogenetics
- Immunology
Background:
- Disease-modifying antirheumatic drugs (DMARDs) and biologic therapies are crucial for managing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
- Significant patient variability exists in responses to these treatments, highlighting a need for personalized approaches.
- Pharmacogenetics, the study of gene-drug interactions, offers a promising avenue for understanding and predicting treatment outcomes.
Purpose of the Study:
- To review the pharmacogenetics of commonly used DMARDs and biologic therapies in rheumatology.
- To explore the potential of pharmacogenetics in enabling personalized medicine for rheumatic diseases.
- To discuss how genetic variations influence patient responses to established and novel antirheumatic treatments.
Main Methods:
- Review of existing literature on pharmacogenetics in rheumatology.
- Analysis of genetic variations in drug transporters, metabolizing enzymes, and drug targets.
- Examination of pharmacogenetic applications for methotrexate and biologic agents.
Main Results:
- Pharmacogenetics is a rapidly advancing field with significant implications for rheumatology.
- Genetic factors contribute to the observed variability in patient responses to antirheumatic drugs.
- Understanding these genetic factors can guide the selection of optimal therapies for individual patients.
Conclusions:
- Pharmacogenetic insights are essential for optimizing the efficacy and safety of DMARDs and biologics in rheumatic diseases.
- Personalized therapy based on pharmacogenetic profiles holds the potential to improve treatment outcomes in RA and SLE.
- Further research in pharmacogenetics will be key to advancing personalized medicine in rheumatology.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...